Proteogenix, Inc.

Maternal-child health has many medical challenges, such as pre-term birth, that are neither clearly understood nor amenable to straightforward diagnosis with conventional methods. ProteoGenix has applied innovative clinical genomic and proteomic technologies to the focused mission of developing and marketing diagnostic tests during a woman's pregnancy. No other enterprises have brought these powerful molecular tools to this market sector. ProteoGenix has utilized high-throughput protein analysis techniques to identify protein biomarkers for pregnancy-related complications. Utilizing primate models and human samples, the company identified over 200 individual proteins relevant to pregnancy from analyses of amniotic fluid, cervical-vaginal fluid, and maternal serum samples, allowing correlation of specific biomarkers with common prenatal or maternal diseases. As a result, ProteoGenix can consistently utilize multiple biomarkers in samples that are attributable to disease, rendering it superior to both conventional single-marker, and proteomics-based pattern-recognition technologies. The advantages of a rapid, easy-to-interpret test from serum or other fluids make a compelling opportunity for point-of-care use or CLIA central laboratories.